Shares of Health Care sector company BridgeBio Pharma moved 7.8% today, and are now trading at a price of $30.94. The small-cap stock's daily volume was 1,427,852 compared to its average volume of 1,435,069. The S&P 500 index returned a 1.0% performance.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company is based in Palo Alto and has 392 full time employees. Its market capitalization is $5,382,539,264.
11 analysts are following BridgeBio Pharma and have set target prices ranging from $28.0 to $60.0 per share. On average, they have given the company a rating of buy. At today's prices, BBIO is trading -33.0% away from its average analyst target price of $46.18 per share.
Over the last year, BBIO's share price has increased by 227.0%, which represents a difference of 213.0% when compared to the S&P 500. The stock's 52 week high is $36.36 per share whereas its 52 week low is $6.64. BridgeBio Pharma has averaged free cash flows of $-357320500.0 over the last 6 years, with a mean growth rate of -48.1%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | -496,144 | 1,672 | -497,816 | -17.32 |
| 2022 | -419,494 | 4,821 | -424,315 | 16.99 |
| 2021 | -497,934 | 13,246 | -511,180 | -25.53 |
| 2020 | -399,714 | 7,518 | -407,232 | -58.94 |
| 2019 | -253,587 | 2,638 | -256,225 | -443.37 |
| 2018 | -46,414 | 741 | -47,155 |
